Atlas Trials

Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

Clinical trial NCT06537297 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06537297
Sponsor
Hunan Province Tumor Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Non-small Cell Lung Cancer
Start date
2024-09-30
Primary completion
2025-08-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.